<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340986</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190473</org_study_id>
    <secondary_id>IDRCB 2019-A01679-48</secondary_id>
    <nct_id>NCT04340986</nct_id>
  </id_info>
  <brief_title>Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma</brief_title>
  <acronym>CHC/CC</acronym>
  <official_title>Cohort Study of Patients With Primary Hepatocellular Carcinoma or Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to describe the evolution of patients treated for a primary malignant
      hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The collection of data from patients with CHC and cholangiocarcinomas who are cancers with
      poor prognosis is a major challenge to improve patients'care (diagnosis, prognosis);
      facilitate the search for new therapeutic targets and the follow-up of clinical studies; and
      develop personalized treatments.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2030</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Hepatocellular carcinoma and Cholangiocarcinoma : Overall survival is defined as the survival 5 years after the inclusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Hepatocellular carcinoma :Overall survival is defined as the survival after 5 years of inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Cholangiocarcinoma : 2 and 5 years after surgical resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression time under chemotherapy</measure>
    <time_frame>Time of progression under chemotherapy up to 5 years</time_frame>
    <description>Cholangiocarcinoma : Time of progression under chemotherapy is defined by the delay between the start of chemotherapy and tumor progression (appearance of a new lesion or increase in size of more than 30%)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>patients with Hepatocellular carcinoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with Cholangiocarcinoma</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with hepatocellular carcinoma or cholangiocarcinoma treated in Saint-Antoine
        hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria :

          -  Age ≥ 18 years olds

          -  Medical care in Nephrology department since 2015

        Cholangiocarcinoma:

        - Histologically and cytologically documented cholangiocarcinoma, regardless of the stage
        of the disease

        Hepatocellular carcinoma:

          -  Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic
             criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm,
             developed on cirrhosis liver with arterial phase hyperenhancement and washout in the
             portal venous or delayed phases on CT and MRI

          -  Hepatocellular histologically documented

        Exclusion Criteria:

        - Lack of patient non-opposition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marie LEQUOY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AssistancePublique-Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie LEQUOY, MD</last_name>
    <phone>+330149283154</phone>
    <email>marie.lequoy@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Serviec hépatologie-Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie LEQUOY, MD</last_name>
      <phone>+330149283154</phone>
      <email>marie.lequoy@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

